MedTrace Logo

Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia

NCT00174382 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 149

Last updated 2015-03-24

Study results available
· View outcomes & findings →

Summary

To document effectiveness, safety, and tolerability of donepezil in patients with mixed AD/VaD, and to further document the effectiveness, safety, and tolerability of donepezil in patients with VaD. The effects of donepezil on executive functioning, behavior, general cognition, ADLs and global functioning will be assessed.

Conditions

  • Dementia, Vascular
  • Dementia, Mixed

Interventions

DRUG

Donepezil

donepezil 5mg/day for 6 weeks and then 5 to 10mg/day for 18 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00174382 on ClinicalTrials.gov